Vulvar Cancer Market Research Report Information by Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, and Basal Cell Carcinoma), Treatment Type (Chemotherapy, Surgery, Radiation Therapy, and Biologic Therapy), End User (Hospitals & Clinics, Research & Academic Institutes, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2030

Vulvar Cancer Market Overview

The vulvar cancer market is expected to reach USD 824.5 Million by 2030 at 8.7% CAGR during the forecast period 2022-2030. Vulvar cancer develops on the outer skin of the female genitalia and appears as a lump or sore on the vulva, causing itching. Vulvar cancer is a rare form of cancer that develops in the tissues of the vulva. It mostly affects the exterior genital organs that safeguard a woman's reproductive system. Vulvar cervical dysplasia and human papillomavirus infection are the main causes of vulvar cancer. Painful sexual intercourse, bleeding, burning, painful urination, persistent itching, rawness and sensitivity, thicker skin, ulceration, and dark coloring in cases of melanoma are all indications of vulvar cancer. Primary vulvar cancer occurs when cancer begins in the vulva; secondary vulvar cancer occurs when cancer spreads to other parts of the body. Squamous cell carcinoma, vulvar melanoma, adenocarcinoma, sarcoma, and verrucous carcinoma are the five kinds of vulvar cancer. The type and stage of vulvar cancer, as well as any side effects, the patient's preferences, and overall health, all influence vulvar cancer treatment.

Many sexual partners, vulvar intraepithelial neoplasia (VIN), HPV infection, genital warts, smoking, and vulvar intraepithelial neoplasia are all risk factors. Squamous cell tumors account for the majority of vulvar malignancies. Adenocarcinoma, melanoma, sarcoma, and basal cell carcinoma are some of the other forms. Physical examination leads to a suspicion of cancer, which is then verified by tissue biopsy. Screening regularly is not advised.

The HPV vaccine is one option for prevention. Surgery, radiation therapy, chemotherapy, and biologic therapy are all common therapies. In 2018, vulvar cancer struck 44,200 persons worldwide, resulting in 15,200 fatalities. After the age of 45, the symptoms usually appear.

COVID-19 Analysis

The outbreak of the COVID-19 pandemic has had a substantial influence on virtually every business in the world. Furthermore, lockdown enforcement and restrictions on the passage of non-essential commodities and resources in numerous countries have disrupted the supply chain for electronic components and networking equipment. As a result, the delivery of medical equipment has been delayed. The COVID-19 epidemic has wreaked havoc on healthcare systems around the world, as well as the Vulvar Cancer Market Growth. Cancer screening and other health prevention services, as well as elective surgeries, should be postponed unless the risks outweighed the benefits, according to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations, to secure the hospital infrastructure for the treatment of COVID-19 patients. As a result, the COVID-19 pandemic has influenced ongoing clinical trials. The situation, though, is likely to progressively improve and also improve Market Analysis during the forecast period.

Vulvar Cancer Market Dynamics

Drivers

The increasing prevalence of Vulvar Cancer Market Outlook, rising investment in research & development activities, and growing government initiatives to raise public awareness about vulvar cancers are the primary drivers driving the global Market Size. Cancer is the second-leading cause of death globally, according to the World Health Organization (WHO), with over 18.1 million cases identified during the historic forecast period. According to the WHO, roughly 19 million new cancer cases will be diagnosed worldwide. Vulvar cancer affects roughly 6% of female reproductive organ cancers and 0.7% of all cancers in women in the United States. According to the American Cancer Society, approximately 6,120 new cases of vulvar cancer will be detected in the United States during the forecast period. During the projection period, this figure will boost the Vulvar Cancer Market Growth.

Restraints

The most common therapy for vulvar cancer is surgery. Formation of fluid-filled cysts near surgical sites, blood clots that may go to the lungs, urinary infections, decreased sexual desire, and lymphedema is some of the problems and side effects of vulvar and groin node surgery. Nausea and vomiting, hair loss, mouth or vaginal sores, changes in the menstrual cycle, premature menopause, and infertility are all common adverse effects of some of the medications used to treat vulvar cancer. Diarrhea is another common side effect. However, the treatment's negative effects are projected to stifle commercial growth. It also affects the bone marrow's blood-forming cells, resulting in low blood counts. One of the primary reasons limiting Vulvar Cancer Market Trends is this.

Vulvar cancer market research includes the Analysis for each country's growth in healthcare capital expenditure, installed base of various types of products for the digital health technologies market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios, as well as their impact on the Vulvar Cancer Market Size. The global vulvar cancer treatment market is likely to be driven by technical advancements, treatment treatments, and diagnosis, as well as increased investment in medication discovery, which raises the odds of vulvar cancer being successfully treated. In the forecast period, the Vulvar Cancer Market Share is expected to be driven by the rising incidence of vulvar cancer in women.

Vulvar Cancer Market Segment Overview

The study depicts the Vulvar Cancer Market's segmentation by cancer type, treatment type, end-users, and geography.

Based on the cancer type, the market has been segmented as follows:

• Vulvar Squamous Cell Carcinoma


• Vulvar Melanoma


• Adenocarcinoma


• Basal Cell Carcinoma

Based on the treatment type, the market has been segmented as follows:

• Chemotherapy


• Surgery


• Laser Surgery


• Excision


• Skinning Vulvectomy


• Radical Vulvectomy


• Radiation Therapy


• Biologic Therapy

Based on the end-user, the market has been segmented as follows:

• Hospitals & Clinics


• Research & Academic Institutes


• Others

Based on the region, the market has been segmented as follows:

The Americas

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Latin America

Europe

• Western Europe
  
  
  
  • France
  
  
  • Germany
  
  
  • Spain
  
  
  • UK
  
  
  • Italy
  
  
  
  


• The Rest of Western Europe


• Eastern Europe

Asia-Pacific

• Japan


• China


• India


• South Korea


• Australia

• The Rest of Asia-Pacific

The Middle East & Africa

• The Middle East


• Africa

Vulvar Cancer Market Regional Classification

Due to the increased prevalence of vulvar cancer, The Americas are likely to lead the vulvar cancer market.

Due to the presence of significant market participants such as F.Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc, and Sanofi, Europe is likely to hold the second-largest proportion of the market.

Because of rising cancer awareness and increased R&D in the field of oncology, Asia-Pacific is predicted to be the fastest-growing regional market.

Due to the high incidence rate of vulvar cancer in the Middle East and Africa, the vulvar cancer market is predicted to develop steadily throughout the forecast period.

Vulvar Cancer Market Competitive Landscape

The major key players of the global vulvar cancer market are Amgen Inc. (US), GlaxoSmithKline plc (UK), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (the US), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi (France), and Johnson & Johnson Services, Inc. (the US). Product launches, acquisitions, and partnerships are among the leading players' growth tactics, all of which are contributing to the market's global expansion.

Recent Developments

Novartis, a Swiss-based corporation, introduced Oncofocus, the world's most precise oncology test for detecting the kind of cancer, increasing the likelihood of effective therapy.

On January 1, 1891, George Merck, at 23 years old, established Merck & Co in the United States to distribute excellent chemicals across New York City and the surrounding areas. In the pursuit of their purpose to save and improve lives, they have been creating for life, bringing forth medicines and vaccines for many of the world's most difficult diseases.

With 74,000 workers and USD 13.6 billion in research and development, Merck & Co. shows their dedication to patients and public health by expanding access to health care through far-reaching policies, programs, and collaborations.

Report Overview

It also analyses trends and co-development arrangements to find business opportunities in the Vulvar Cancer Market. Product mapping is available for all major market participants' important products. It also aids firms in complying with current health and safety laws. The study breaks down the industry into several sectors and delivers the most accurate revenue estimates for the overall market across various geographies. In this research analysis, the global market potential, industry dynamics, and leading vendors operating in the market are all covered in depth.